Complicaciones gástricas de tratamientos farmacológicos

  1. I. Gil-Aldea 1
  2. J.R. Azanza Perea 2
  1. 1 Navarrabiomed. Fundación Miguel Servet. Servicio Navarro de Salud-Osasunbidea. Pamplona.
  2. 2 Clínica Universitaria de Navarra
    info

    Clínica Universitaria de Navarra

    Pamplona, España

    ROR https://ror.org/03phm3r45

Revista:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Año de publicación: 2016

Título del ejemplar: Enfermedades del aparato digestivo (III): Patología gastroduodenal (II)

Serie: 12

Número: 3

Páginas: 137-142

Tipo: Artículo

DOI: 10.1016/J.MED.2016.02.004 DIALNET GOOGLE SCHOLAR

Otras publicaciones en: Medicine: Programa de Formación Médica Continuada Acreditado

Resumen

Introducción Las complicaciones gástricas de los medicamentos constituyen unos de los efectos adversos más destacados y de mayor relevancia clínica, siendo los AINE los principales causantes. Patogénesis El daño a nivel de la mucosa gástrica se puede presentar de diferentes maneras, siendo el mecanismo fundamental la inhibición de la síntesis de prostaglandinas. Factores de riesgo Existen diversos factores de riesgo, dependientes e independientes, que permiten estratificar a los pacientes según su riesgo y, en consecuencia, adoptar medidas preventivas. Prevención y tratamiento Entre estas medidas, la coadministración de AINE junto con inhibidores de la bomba de protones o la administración de inhibidores selectivos de la COX-2 han demostrado ser en estudios aleatorizados medidas efectivas. No obstante, se deben valorar otras alternativas preventivas y terapéuticas a la administración de AINE, debido sobre todo al riesgo asociado cardiovascular de este grupo farmacológico y, en especial, de los inhibidores selectivos de la COX-2.

Referencias bibliográficas

  • Carrasco-Garrido P, de Andrés LA, Barrera VH, de Miguel GA, Jiménez-García R. Trends of adverse drug reactions related-hospitalizations in Spain (2001-2006). BMC Health Serv Res. 2010;10:287.
  • García Rodríguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet. 1994;343(8900):769-72.
  • Goldstein JL, Cryer B. Gastrointestinal injury associated with NSAID use: a case study and review of risk factors and preventative strategies. Drug Healthc Patient Saf. 2015;7:31-41.
  • Singh G. Gastrointestinal complications of prescription and over-the-counter nonsteroidal anti-inflammatory drugs: a view from the ARAMIS database. Arthritis, rheumatism, and aging medical information system. Am J Ther. 2000;7(2):115-21.
  • Laine L, Takeuchi K, Tarnawski A. Gastric mucosal defense and cytoprotection: bench to bedside. Gastroenterology. 2008;135(1):41-60.
  • Modlin IM, Kidd M, Lye KD, Wright NA. Gastric stem cells: an update. Keio J Med. 2003;52(2):134-7.
  • Guth PH. Current concepts in gastric microcirculatory pathophysiology. Yale J Biol Med. 1992;65(6):677-88.
  • Holzer P. Role of visceral afferent neurons in mucosal inflammation and defense. Curr Opin Pharmacol. 2007;7(6):563-9.
  • Stroff T, Plate S, Respondek M, Müller KM, Peskar BM. Protection by gastrin in the rat stomach involves afferent neurons, calcitonin genere-lated peptide, and nitric oxide. Gastroenterology. 1995;109(1):89-97.
  • Ham M, Kaunitz JD. Gastroduodenal defense. Curr Opin Gastroenterol. 2007;23(6):607-16.
  • Peskar BM. Neural aspects of prostaglandin involvement in gastric mu-cosal defense. J Physiol Pharmacol. 2001;52(4 Pt 1):555-68.
  • Filaretova L, Podvigina T, Bagaeva T, Bobryshev P, Takeuchi K. Gastro-protective role of glucocorticoid hormones. J Pharmacol Sci. 2007;104(3): 195-201.
  • Halter F, Tarnawski AS, Schmassmann A, Peskar BM. Cyclooxygenase 2-implications on maintenance of gastric mucosal integrity and ulcer hea-ling: controversial issues and perspectives. Gut. 2001;49(3):443-53.
  • Brzozowski T, Konturek PC, Konturek SJ, Brzozowska I, Pawlik T. Role of prostaglandins in gastroprotection and gastric adaptation. J Physiol Pharmacol. 2005;56 Suppl5:33-55.
  • Rostom A, Muir K, Dubé C, Jolicoeur E, Boucher M, Joyce J, et al. Gas-trointestinal safety of cyclooxygenase-2 inhibitors: a Cochrane Collabo-ration systematic review. Clin Gastroenterol Hepatol. 2007;5(7):818-28.
  • Strom BL, Berlin JA, Kinman JL, Spitz PW, Hennessy S, Feldman H, et al. Parenteral ketorolac and risk of gastrointestinal and operative site bleeding. A positmarketing surveillance study. JAMA. 1996;275(5):376-82.
  • Singh G, Ramey DR, Morfeld D, Shi H, Hatoum HT, Fries JF. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study. Arch Intern Med. 199622;156(14):1530-6.
  • Silverstein FE, Graham DY, Senior JR, Davies HW, Struthers BJ, Bittman RM, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1995;123(4):241-9.
  • Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. 2000;343(21):1520-8.
  • Fries JF, Williams CA, Bloch DA, Michel BA. Nonsteroidal anti-inflammatory drug-associated gastropathy: incidence and risk factor models. Am J Med. 1991;91(3):213-222.
  • Jankovic SM, Aleksic J, Rakovic S, Aleksic A, Stevanovic I, Stefanovic-Stoimenov N, et al. Nonsteroidal antiinflammatory drugs and risk of gastrointestinal bleeding among patients on hemodialysis. J Nephrol. 2009;22(4):502-7.
  • Lanas A, García-Rodríguez LA, Arroyo MT, Bujanda L, Gomollón F, Forné M, et al. Investigators of the Asociación Española de Gastroenterología (AEG). Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants. Am J Gastroenterol. 2007;102(3):507-15.
  • García Rodríguez LA, Hernández-Díaz S. The risk of upper gastrointes-tinalcomplications associated with nonsteroidal anti-inflammatory drugs, glucocorticoids, acetaminophen, and combinations of these agents. Ar-thritis Res. 2001;3(2):98-101.
  • De Abajo FJ, Rodríguez LA, Montero D. Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study. BMJ. 1999;319(7217):1106-9.
  • De Jong JC, van den Berg PB, Tobi H, de Jong-van den Berg LT. Com-bined use of SSRIs and NSAIDs increases the risk of gastrointestinal adverse effects. Br J Clin Pharmacol. 2003;55(6):591-5.
  • Shorr RI, Ray WA, Daugherty JR, Griffin MR. Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease. Arch Intern Med. 1993;153(14):1665-70.
  • Scheiman JM. The use of proton pump inhibitors in treating and preventing NSAID-induced mucosal damage. Arthritis Res Ther. 2013;15Suppl3: S5.
  • Wikman Jorgensen P, López Calleja E, Safont Gasó P, Matarranz del Amo M, Andrés Navarro R, Merino Sánchez J. Antiagregación y anticoagulación, relación con la hemorragia digestiva alta. Rev Esp Enferm Dig. 2011;103:360-5.
  • Lanas A, García-Tell G, Armada B, Oteo-Alvaro A. Prescription patterns and appropriateness of NSAID therapy according to gastrointestinal risk and cardiovascular history in patients with diagnoses of osteoarthritis. BMC Med. 2011;9:38.
  • Lanza FL, Chan FK, Quigley EM; Practice Parameters Committee of the American College of Gastroenterology. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol. 2009;104(3): 728-38.
  • Conaghan PG, Dickson J, Grant RL; Guideline Development Group. Care and management of osteoarthritis in adults: summary of NICE guidance. BMJ. 2008;336(7642):502-3.
  • Gibofsky A, Silberstein S, Argoff C, Daniels S, Jensen S, Young CL. Lower-dose diclofenac submicron particle capsules provide early and sustained acute patient pain relief in a phase 3 study. Postgrad Med. 2013; 125(5):130-8.
  • Massey T, Derry S, Moore RA, McQuay HJ. Topical NSAIDs for acute pain in adults. Cochrane Database Syst Rev. 2010;(6):CD007402.
  • Eom CS, Jeon CY, Lim JW, Cho EG, Park SM, Lee KS. Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis. CMAJ. 2011;183(3):310-9.
  • Chan FK, Lanas A, Scheiman J, Berger MF, Nguyen H, Goldstein JL. Celecoxib versus omeprazole and diclofenac in patients with osteoarthri-tis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet. 2010;376(9736):173-9.
  • Wang X, Tian HJ, Yang HK, Wanyan P, Peng YJ. Meta-analysis: cycloo-xygenase-2 inhibitors are no better than nonselective nonsteroidal anti-inflammatory drugs with proton pump inhibitors in regard to gastroin-testinal adverse events in osteoarthritis and rheumatoid arthritis. Eur J Gastroenterol Hepatol. 2011;23(10):876-80.
  • Rostom A, Wells G, Tugwell P, Welch V, Dubé C, McGowan J. The pre-vention of chronic NSAID induced upper gastrointestinal toxicity: a Co-chrane collaboration metaanalysis of randomized controlled trials. J Rheumatol. 2000;27(9):2203-14.
  • Rostom A, Dube C, Wells G, Tugwell P, Welch V, Jolicoeur E, et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev. 2002;(4):CD002296.
  • Vergara M, Catalán M, Gisbert JP, Calvet X. Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment Pharmacol Ther. 2005;21(12):1411-8.
  • Scheiman JM. Balancing risks and benefits of cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs. Gastroenterol Clin North Am. 2009;38(2):305-14.
Fuente de los datos: Dialnet